Wednesday, March 29, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Pathogens

Immune Response to New Coronavirus Unveils Possible Paths to Treatments

by Global Biodefense Staff
May 1, 2013

CoronavirusUniversity of Washington scientists used lab-grown human lung cells to study cell response to infection by a novel human coronavirus (nCoV) and compiled information about which genes are significantly disrupted in early and late stages of infection.

The host response study, supported by the National Institutes of Health, has allowed the researchers to predict drugs that might be used to inhibit either the nCoV virus itself or the damaging responses that host cells make in reaction to infection.

Since nCoV was recognized in 2012, 17 confirmed cases and 11 deaths have been reported—a high fatality rate that is spurring urgent research efforts to better understand the virus and its effects. 

The investigators, led by Michael G. Katze, Ph.D., of the University of Washington, compared cellular gene expression responses to two viruses: the novel coronavirus and a coronavirus that caused a global outbreak of severe acute respiratory syndrome (SARS) in 2003.

Although the viruses are in the same family, their effects on human cells are vastly different. In general, nCoV disrupted a greater number of human genes more profoundly and at more time points after infection than the SARS coronavirus. The team identified one set of 207 human genes whose expression differed from normal soon after infection with nCoV and remained disrupted throughout the course of infection. Notably, nCoV down-regulated the activity of a group of genes involved in signaling the presence of an invading virus to the immune system. Such down-regulation may cause a delay in the infection-fighting response.

The researchers used computational approaches to determine that certain classes of drugs, including specific kinase inhibitors and one type of glucocorticoid, act on some of the 207 human genes whose expression was found to be disrupted by nCoV. The team hypothesized that treatment with such drugs might block nCoV replication and disease progression in the host.

In their current study, they tested this hypothesis using a kinase inhibitor on nCoV-infected cells grown in test tubes. They found that the drug did inhibit the ability of the virus to replicate. Additional studies are needed to see if kinase inhibitors could be useful alone or in combination with other drugs to treat nCoV infection in people.

The findings were recently published in mBio: Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus. 

Source: NIH – National Institute of Allergy and Infectious Diseases

Tags: AntiviralsCoronavirusEmerging ThreatsMERS-CoV

Related Posts

Medical Countermeasures

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
The device appears smaller than a playing card, transparent, with visible channels branching off.
Medical Countermeasures

How Organ-on-a-chip Models Could Grease the Drug Development Pipeline

January 10, 2023
Load More

Latest News

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC